The Pharmaletter
One To Watch
GigaGen
A US biotech advancing transformative antibody drugs for infectious disease, immunodeficiency disorders, transplant rejection, and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies.
GigaGen's pipeline includes GIGA-2050, which is in development for COVID-19, and the oncology candidate GIGA-564. Both drugs were in IND-enabling studies in August 2020.
The San Francisco firm claims that these candidates have the potential to translate into therapies with improved efficacy and safety profiles.
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze